^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

JNJ-5322

i
Other names: JNJ-5322, JNJ-79635322, JNJ5322, JNJ79635322, JNJ 5322, JNJ 79635322
Company:
J&J
Drug class:
CD3 agonist, BCMA inhibitor, GPRC5D inhibitor
Related drugs:
2ms
Trial completion date • Trispecific
|
JNJ-5322
9ms
Trial completion date • Trispecific
|
JNJ-5322
1year
Characterization of JNJ-79635322, a Novel BCMAxGPRC5DxCD3 T-Cell Redirecting Trispecific Antibody, for the Treatment of Multiple Myeloma (ASH 2023)
JNJ-79635322 is a potential first-in-class trispecific antibody targeting BCMA and GPRC5D with the ability to deplete dual and single target expressing MM clones in preclinical studies vitro and in vivo. A Phase 1 dose-escalating study of JNJ-79635322 in myeloma patients is ongoing (NCT05652335).
Trispecific
|
GPRC5D (G Protein-Coupled Receptor Class C Group 5 Member D)
|
GPRC5D expression
|
JNJ-5322
1year
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
P1, N=169, Recruiting, Janssen Research & Development, LLC | N=90 --> 169
Enrollment change • Trispecific
|
JNJ-5322